SILO Pharma Inc SILO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SILO is a good fit for your portfolio.
News
-
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
-
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
-
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
-
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
-
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
Trading Information
- Previous Close Price
- $1.85
- Day Range
- $1.85–1.92
- 52-Week Range
- $1.22–3.05
- Bid/Ask
- $1.80 / $1.95
- Market Cap
- $5.37 Mil
- Volume/Avg
- 39,285 / 206,382
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 80.73
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 8.77%
Company Profile
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.silopharma.com
Valuation
|
Metric
|
SILO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.89 |
Price/Sales | 80.73 |
Price/Cash Flow | — |
Price/Earnings
SILO
Financial Strength
|
Metric
|
SILO
|
|---|---|
Quick Ratio | 9.88 |
Current Ratio | 9.90 |
Interest Coverage | −826.61 |
Quick Ratio
SILO
Profitability
|
Metric
|
SILO
|
|---|---|
Return on Assets (Normalized) | −33.82% |
Return on Equity (Normalized) | −40.21% |
Return on Invested Capital (Normalized) | −44.92% |
Return on Assets
SILO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wjpylnstyw | Vlrp | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gnbwysv | Ywqxln | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ynzjdjft | Mzfqq | $98.3 Bil | |
MRNA
| Moderna Inc | Pvwrznzs | Vjrj | $42.7 Bil | |
ARGX
| argenx SE ADR | Gpjkckwy | Yfqm | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Xfpxfxjm | Xjr | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lmcwjmkz | Jnmwyfk | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fcyqdlx | Gpdkjq | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zfqvzzpblv | Thvvb | $12.7 Bil | |
INCY
| Incyte Corp | Ffvpmlnds | Ylwcy | $11.8 Bil |